|
|
|
|
|
|
|
|
|
|
121st Maine Legislature |
|
|
|
Office of Fiscal and Program Review |
|
|
|
LD 254 |
|
|
|
An
Act To Require Full Disclosure of Prescription Drug Marketing Costs |
|
|
|
|
|
|
|
|
|
LR 0072(01) |
|
|
|
Fiscal Note for Original Bill |
|
|
|
Sponsor: Rep. Kane |
|
|
|
Committee: Health and Human Services |
|
|
|
Fiscal Note Required: Yes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Note |
|
|
|
|
|
|
|
|
|
Undetermined
current biennium cost increase - Other Special Revenue Funds |
|
Undetermined
current biennium revenue increase - Other Special Revenue Funds |
|
Minor
cost increase - General Fund |
|
Minor
revenue increase - General Fund |
|
|
|
|
|
|
|
|
|
Correctional and
Judicial Impact Statements |
|
|
|
|
|
|
Establishes new civil violation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Detail
and Notes |
|
|
|
|
|
|
|
Any
initial start-up costs to the Bureau of Medical Services in the Department of
Human Services can be absorbed within existing budgeted resources. The bill requires prescription drug
manufacturers pay fees to the Department in addition to submitting
reports. The amount of these fees are
to be determined by the Department.
The timing and amount of revenue collected from these fees, as well as
the ongoing costs of the Department can not be determined at this time. The bill assumes the fees will be
sufficient to cover additional costs to the Department. Any additional costs to the Office of the
Attorney General can be absorbed within existing budgeted resources. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|